首页 > 最新文献

Expert Review of Respiratory Medicine最新文献

英文 中文
Pharmacotherapy and immunotherapy of allergic rhinitis induced by house dust mite, grass, and birch pollen allergens: a meta-analysis of randomized clinical trials. 屋尘螨、草和桦树花粉过敏原诱导的过敏性鼻炎的药物治疗和免疫治疗:一项随机临床试验的荟萃分析。
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-07-28 DOI: 10.1080/17476348.2023.2241364
Monika Marko, Rafał Pawliczak

Background: The aim of this study was to assess the efficacy and safety of oral antihistamines (AHs), intranasal antihistamines (INAH) intranasal glucocorticosteroids (INCS), subcutaneous immunotherapy (SCIT), and sublingual immunotherapy (SLIT) in the management of allergic rhinitis (AR). The authors focused on the division into selected AR's triggers: house dust mites (HDMs), grass pollen, and birch pollen.

Methods: For each drug and allergen class, a meta-analysis of the efficacy and adverse events (AEs) was performed. The obtained results were presented as a therapeutic index (TIX-Score).

Results: Twenty-seven randomized clinical trials (RCTs) were included. The best total efficacy was observed for: HDMs for INCS and grass pollen for combination of INCS with INAH in a single device and for INAH. Considering the data that was obtained for birch pollen, SLIT showed statistically significant total efficacy. Summation scores for efficacy and AEs showed highest TIX-Score for combination of INCS and INAH in a single device in grass pollen.

Conclusions: Treatment methods selected for this review may serve as an effective and safe treatment in reducing perennial and seasonal AR's symptoms. However, due to high heterogeneity probably associated with potential confounders existence in control in some cases, results should be interpreted with caution.

背景:本研究的目的是评估口服抗组胺药(AHs)、鼻内抗组胺剂(INAH)、鼻内糖皮质激素(INCS)、皮下免疫疗法(SCIT)和舌下免疫疗法(SLIT)治疗过敏性鼻炎(AR)的疗效和安全性。作者重点研究了AR的触发因素:屋尘螨(HDM)、草花粉和桦树花粉。方法:对每种药物和过敏原类别进行疗效和不良事件(AE)的荟萃分析。结果:纳入了27项随机临床试验(RCT)。观察到的最佳总疗效是:HDMs用于INCS,草花粉用于INCS与INAH在单个设备中的组合和INAH。考虑到桦树花粉的数据,SLIT显示出具有统计学意义的总功效。疗效和AE的综合得分显示,在草花粉的单个装置中,INCS和INAH组合的TIX得分最高。结论:本综述中选择的治疗方法可以作为一种有效和安全的治疗方法,减少常年和季节性AR的症状。然而,由于在某些情况下可能与对照中存在的潜在混杂因素相关的高度异质性,应谨慎解释结果。
{"title":"Pharmacotherapy and immunotherapy of allergic rhinitis induced by house dust mite, grass, and birch pollen allergens: a meta-analysis of randomized clinical trials.","authors":"Monika Marko,&nbsp;Rafał Pawliczak","doi":"10.1080/17476348.2023.2241364","DOIUrl":"10.1080/17476348.2023.2241364","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to assess the efficacy and safety of oral antihistamines (AHs), intranasal antihistamines (INAH) intranasal glucocorticosteroids (INCS), subcutaneous immunotherapy (SCIT), and sublingual immunotherapy (SLIT) in the management of allergic rhinitis (AR). The authors focused on the division into selected AR's triggers: house dust mites (HDMs), grass pollen, and birch pollen.</p><p><strong>Methods: </strong>For each drug and allergen class, a meta-analysis of the efficacy and adverse events (AEs) was performed. The obtained results were presented as a therapeutic index (TIX-Score).</p><p><strong>Results: </strong>Twenty-seven randomized clinical trials (RCTs) were included. The best total efficacy was observed for: HDMs for INCS and grass pollen for combination of INCS with INAH in a single device and for INAH. Considering the data that was obtained for birch pollen, SLIT showed statistically significant total efficacy. Summation scores for efficacy and AEs showed highest TIX-Score for combination of INCS and INAH in a single device in grass pollen.</p><p><strong>Conclusions: </strong>Treatment methods selected for this review may serve as an effective and safe treatment in reducing perennial and seasonal AR's symptoms. However, due to high heterogeneity probably associated with potential confounders existence in control in some cases, results should be interpreted with caution.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and prognostic value of Ang-2 in ARDS: a systemic review and meta-analysis. Ang-2在ARDS中的诊断和预后价值:一项系统综述和荟萃分析。
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-07-04 DOI: 10.1080/17476348.2023.2230883
Qianglin Zeng, Gui Huang, Shanna Li, Fuqiang Wen

Background: To investigate the diagnostic and prognostic value of angiopoietin-2 (Ang-2) for acute respiratory distress syndrome (ARDS).

Methods: Seven databases (4 English and 3 Chinese databases) were searched, the quality was evaluated by QUADAS-2 and GRADE profile. The bivariate model was employed to combine area under the curve (AUC), pooled sensitivity (pSEN) and pooled specificity (pSPE), the Fagan's nomogram was employed for evaluating clinical utility. This study was registered in PROSPERO (NO.CRD42022371488).

Results: 18 eligible studies comprising 27 datasets (12 diagnostic and 15 prognostic datasets) were included for meta-analysis. For diagnostic analysis, Ang-2 yielded an AUC of 0.82, with a pSEN of 0.78 and a pSPE of 0.74; in clinical utility analysis, a pretest probability of 50% regulated the post probability positive (PPP) of 75% and the post probability negative (PPN) of 23%. In prognostic analysis, Ang-2 yielded an AUC of 0.83, with a pSEN of 0.69, a pSPE of 0.81, and good clinical utility (a pretest probability of 50% regulated the PPP of 79% and the PPN of 28%). Heterogeneity existed in both diagnostic and prognostic analysis.

Conclusions: Ang-2 demonstrates promising diagnostic and prognostic capabilities as a noninvasive circulating biomarker for ARDS, especially in the Chinese population. It is advisable to dynamically monitor Ang-2 in critically ill patients both suspected and with confirmed ARDS.

背景:探讨血管生成素-2(Ang-2)对急性呼吸窘迫综合征(ARDS)的诊断和预后价值。采用双变量模型结合曲线下面积(AUC)、合并灵敏度(pSEN)和合并特异性(pSPE),采用Fagan列线图评估临床效用。本研究在PROSPERO(编号CRD42022371488)上注册。结果:纳入了18项符合条件的研究,包括27个数据集(12个诊断数据集和15个预后数据集)进行荟萃分析。对于诊断分析,Ang-2的AUC为0.82,pSEN为0.78,pSPE为0.74;在临床效用分析中,50%的前测概率调节了75%的后概率阳性(PPP)和23%的后概率阴性(PPN)。在预后分析中,Ang-2的AUC为0.83,pSEN为0.69,pSPE为0.81,具有良好的临床实用性(50%的预测试概率调节了79%的PPP和28%的PPN)。诊断和预后分析均存在异质性。结论:Ang-2作为ARDS的无创循环生物标志物,尤其是在中国人群中,具有良好的诊断和预后能力。在疑似和确诊ARDS的危重患者中动态监测Ang-2是可取的。
{"title":"Diagnostic and prognostic value of Ang-2 in ARDS: a systemic review and meta-analysis.","authors":"Qianglin Zeng,&nbsp;Gui Huang,&nbsp;Shanna Li,&nbsp;Fuqiang Wen","doi":"10.1080/17476348.2023.2230883","DOIUrl":"10.1080/17476348.2023.2230883","url":null,"abstract":"<p><strong>Background: </strong>To investigate the diagnostic and prognostic value of angiopoietin-2 (Ang-2) for acute respiratory distress syndrome (ARDS).</p><p><strong>Methods: </strong>Seven databases (4 English and 3 Chinese databases) were searched, the quality was evaluated by QUADAS-2 and GRADE profile. The bivariate model was employed to combine area under the curve (AUC), pooled sensitivity (pSEN) and pooled specificity (pSPE), the Fagan's nomogram was employed for evaluating clinical utility. This study was registered in PROSPERO (NO.CRD42022371488).</p><p><strong>Results: </strong>18 eligible studies comprising 27 datasets (12 diagnostic and 15 prognostic datasets) were included for meta-analysis. For diagnostic analysis, Ang-2 yielded an AUC of 0.82, with a pSEN of 0.78 and a pSPE of 0.74; in clinical utility analysis, a pretest probability of 50% regulated the post probability positive (PPP) of 75% and the post probability negative (PPN) of 23%. In prognostic analysis, Ang-2 yielded an AUC of 0.83, with a pSEN of 0.69, a pSPE of 0.81, and good clinical utility (a pretest probability of 50% regulated the PPP of 79% and the PPN of 28%). Heterogeneity existed in both diagnostic and prognostic analysis.</p><p><strong>Conclusions: </strong>Ang-2 demonstrates promising diagnostic and prognostic capabilities as a noninvasive circulating biomarker for ARDS, especially in the Chinese population. It is advisable to dynamically monitor Ang-2 in critically ill patients both suspected and with confirmed ARDS.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10471827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
How can we improve our use of allergen immunotherapy as a treatment option for asthma and severe asthma? 我们如何改进过敏原免疫疗法作为哮喘和严重哮喘治疗选择的使用?
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-08-29 DOI: 10.1080/17476348.2023.2251403
Désirée Larenas-Linnemann, Blanca María Morfin Maciel

Introduction: In patients suffering from allergic asthma, especially in the pediatric age-group, allergen immunotherapy (AIT) could be of benefit and has the potential of long-term disease modification.

Areas covered: We reviewed the evidence for a beneficial effect of AIT in allergic asthma. A correct selection of the possible candidates for AIT is crucial. We define the comprehensive allergic asthma diagnosis: confirming asthma, confirming allergic sensitization and having symptoms on exposure to the relevant allergens.We analyze why the first trials on AIT for asthma were contradictory; we consider the results of systematic reviews and discuss the high degree of heterogeneity often found in meta-analysis. We assess recent, double-blind, placebo-controlled trials in sublingual AIT that provide robust evidence for a reduction in acute asthma exacerbations and a decrease in the use of inhaled corticosteroids. Further, we demonstrate how real-world trials and large pharmacy data-based analyses confirm these findings for SLIT and SCIT. Finally, we explore the option of AIT in severe asthma patients, once well-controlled on biologic therapy.

Expert opinion: Clear indications for AIT in asthma guidelines would benefit allergic asthmatics. AIT is a therapeutic option in appropriately selected asthmatics. Three years treatment has the potential for long-term tolerance, with persisting benefits years after discontinuation.

引言:对于过敏性哮喘患者,尤其是儿科年龄组的患者,过敏原免疫疗法(AIT)可能是有益的,并且具有长期改变疾病的潜力。涵盖的领域:我们回顾了AIT对过敏性哮喘有益的证据。正确选择可能的AIT候选人至关重要。我们定义了全面的过敏性哮喘诊断:确认哮喘、确认过敏性致敏和在接触相关过敏原时出现症状。我们分析了为什么AIT治疗哮喘的最初试验是矛盾的;我们考虑了系统综述的结果,并讨论了荟萃分析中经常发现的高度异质性。我们评估了最近在舌下AIT中进行的双盲安慰剂对照试验,这些试验为减少急性哮喘恶化和减少吸入皮质类固醇的使用提供了有力的证据。此外,我们展示了真实世界的试验和基于大型药房数据的分析如何证实SLIT和SCIT的这些发现。最后,我们探讨了AIT在严重哮喘患者中的选择,一旦生物治疗得到很好的控制。专家意见:哮喘指南中明确的AIT适应症将有利于过敏性哮喘患者。AIT是适当选择的哮喘患者的一种治疗选择。三年的治疗具有长期耐受的潜力,在停药数年后仍有益处。
{"title":"How can we improve our use of allergen immunotherapy as a treatment option for asthma and severe asthma?","authors":"Désirée Larenas-Linnemann, Blanca María Morfin Maciel","doi":"10.1080/17476348.2023.2251403","DOIUrl":"10.1080/17476348.2023.2251403","url":null,"abstract":"<p><strong>Introduction: </strong>In patients suffering from allergic asthma, especially in the pediatric age-group, allergen immunotherapy (AIT) could be of benefit and has the potential of long-term disease modification.</p><p><strong>Areas covered: </strong>We reviewed the evidence for a beneficial effect of AIT in allergic asthma. A correct selection of the possible candidates for AIT is crucial. We define the comprehensive allergic asthma diagnosis: confirming asthma, confirming allergic sensitization and having symptoms on exposure to the relevant allergens.We analyze why the first trials on AIT for asthma were contradictory; we consider the results of systematic reviews and discuss the high degree of heterogeneity often found in meta-analysis. We assess recent, double-blind, placebo-controlled trials in sublingual AIT that provide robust evidence for a reduction in acute asthma exacerbations and a decrease in the use of inhaled corticosteroids. Further, we demonstrate how real-world trials and large pharmacy data-based analyses confirm these findings for SLIT and SCIT. Finally, we explore the option of AIT in severe asthma patients, once well-controlled on biologic therapy.</p><p><strong>Expert opinion: </strong>Clear indications for AIT in asthma guidelines would benefit allergic asthmatics. AIT is a therapeutic option in appropriately selected asthmatics. Three years treatment has the potential for long-term tolerance, with persisting benefits years after discontinuation.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10296385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interstitial lung abnormality in COPD is associated with higher prevalence of antinuclear antibody. COPD患者肺间质异常与抗核抗体的高患病率有关。
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-09-12 DOI: 10.1080/17476348.2023.2257135
Yujia Liu, Yanwen Jiang, Yongchang Sun

Object: To investigate whether the prevalence of positive ANA was increased in COPD with interstitial lung abnormality (ILA).

Methods: Patients with COPD from 1 September, 2019 to 31 August, 2022 were consecutively enrolled in this cross-sectional study. The characteristics, PFTs, visual assessment of ILA and emphysema on chest CT, and tests for ANA and CRP were recorded for analysis.

Results: In the study period, 100 patients with COPD were enrolled, with 90 (90.0%) males, aging 69.4 ± 8.3 years. ILA was present in 42% (n = 42) of the patients, with subpleural non-fibrotic ILA being the most common pattern. In patients with ILA, the prevalence of positive ANA was higher (45.2%) as compared to those without ILA (13.3%); between whom the difference in DLCO was also significant. In patients with positive ANA, the scores of ILA were higher, while FEV1, DLCO, DLCO % predicted, FVC, total lung capacity (TLC), and TLC % predicted were significantly lower, as compared to those with negative ANA.

Conclusion: The presence of ILA in patients with COPD was associated with a higher prevalence of positive ANA. Patients with positive ANA tended to have lower FEV1, DLCO and lung volume.

目的:探讨ANA阳性在COPD伴间质性肺异常(ILA)患者中的患病率是否增加。方法:将2019年9月1日至2022年8月31日的COPD患者连续纳入本横断面研究。记录特征、PFTs、胸部CT对ILA和肺气肿的视觉评估以及ANA和CRP的测试以进行分析。结果:在研究期间,100名COPD患者入选,其中90名(90.0%)男性,年龄69.4岁 ± 8.3 年。ILA存在于42%(n = 其中胸膜下非纤维化ILA是最常见的模式。在ILA患者中,ANA阳性的患病率(45.2%)高于无ILA患者(13.3%);DLCO差异也有显著性。与ANA阴性患者相比,ANA阳性患者的ILA评分较高,而FEV1、DLCO、DLCO%预测值、FVC、总肺活量(TLC)和TLC%预测值显著较低。结论:COPD患者ILA的存在与ANA阳性率较高有关。ANA阳性患者的FEV1、DLCO和肺容量往往较低。
{"title":"Interstitial lung abnormality in COPD is associated with higher prevalence of antinuclear antibody.","authors":"Yujia Liu,&nbsp;Yanwen Jiang,&nbsp;Yongchang Sun","doi":"10.1080/17476348.2023.2257135","DOIUrl":"10.1080/17476348.2023.2257135","url":null,"abstract":"<p><strong>Object: </strong>To investigate whether the prevalence of positive ANA was increased in COPD with interstitial lung abnormality (ILA).</p><p><strong>Methods: </strong>Patients with COPD from 1 September, 2019 to 31 August, 2022 were consecutively enrolled in this cross-sectional study. The characteristics, PFTs, visual assessment of ILA and emphysema on chest CT, and tests for ANA and CRP were recorded for analysis.</p><p><strong>Results: </strong>In the study period, 100 patients with COPD were enrolled, with 90 (90.0%) males, aging 69.4 ± 8.3 years. ILA was present in 42% (<i>n</i> = 42) of the patients, with subpleural non-fibrotic ILA being the most common pattern. In patients with ILA, the prevalence of positive ANA was higher (45.2%) as compared to those without ILA (13.3%); between whom the difference in D<sub>LCO</sub> was also significant. In patients with positive ANA, the scores of ILA were higher, while FEV<sub>1</sub>, D<sub>LCO</sub>, D<sub>LCO</sub> % predicted, FVC, total lung capacity (TLC), and TLC % predicted were significantly lower, as compared to those with negative ANA.</p><p><strong>Conclusion: </strong>The presence of ILA in patients with COPD was associated with a higher prevalence of positive ANA. Patients with positive ANA tended to have lower FEV<sub>1</sub>, D<sub>LCO</sub> and lung volume.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10653396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Up-to-date guidance towards improving medication adherence in patients with chronic obstructive pulmonary disease. 改善慢性阻塞性肺病患者药物依从性的最新指南。
IF 2.9 3区 医学 Q2 RESPIRATORY SYSTEM Pub Date : 2023-07-01 Epub Date: 2023-07-28 DOI: 10.1080/17476348.2023.2239708
Meredith A Case, Michelle N Eakin

Introduction: Despite efficacious treatment for chronic obstructive pulmonary disease (COPD), medication adherence remains quite poor, with most estimates based on electronic monitoring devices ranging from 20-30%. This degree of nonadherence represents a significant missed opportunity to realize the benefits of treatment of this disease.

Areas covered: In this article, we review research on the prevalence of nonadherence among patients with COPD, the association of nonadherence with health outcomes, barriers to adherence in this patient population, and potential interventions.

Expert opinion: Integrating research into practice involves assessing patients' adherence, identifying modifiable barriers to adherence, open discussion of these barriers with patients, and tailored interventions to address them. These interventions may include treatment of previously unrecognized comorbid disease, providing educational or behavioral interventions, optimizing prescribing strategies, use of adherence aids, or addressing cost and other access barriers. Electronic inhaler monitors are promising interventions for both monitoring and improving adherence. However, remaining concerns about integration into patient care, data management, cost, acceptability, and ethical and privacy issues must be overcome prior to their implementation in clinical practice.

引言:尽管慢性阻塞性肺病(COPD)得到了有效的治疗,但药物依从性仍然很差,大多数基于电子监测设备的估计值在20-30%之间。这种程度的不依从性代表着严重错过了实现这种疾病治疗益处的机会。涵盖领域:在这篇文章中,我们回顾了关于COPD患者不依从性的患病率、不依从性与健康结果的关系、该患者群体中的依从性障碍以及潜在干预措施的研究。专家意见:将研究纳入实践包括评估患者的依从性,确定可改变的依从性障碍,与患者公开讨论这些障碍,并采取量身定制的干预措施来解决这些障碍。这些干预措施可能包括治疗以前未被识别的共病,提供教育或行为干预,优化处方策略,使用依从性辅助工具,或解决成本和其他获取障碍。电子吸入器监测仪是监测和改善依从性的有希望的干预措施。然而,在临床实践中实施之前,必须克服对整合到患者护理、数据管理、成本、可接受性以及道德和隐私问题的剩余担忧。
{"title":"Up-to-date guidance towards improving medication adherence in patients with chronic obstructive pulmonary disease.","authors":"Meredith A Case, Michelle N Eakin","doi":"10.1080/17476348.2023.2239708","DOIUrl":"10.1080/17476348.2023.2239708","url":null,"abstract":"<p><strong>Introduction: </strong>Despite efficacious treatment for chronic obstructive pulmonary disease (COPD), medication adherence remains quite poor, with most estimates based on electronic monitoring devices ranging from 20-30%. This degree of nonadherence represents a significant missed opportunity to realize the benefits of treatment of this disease.</p><p><strong>Areas covered: </strong>In this article, we review research on the prevalence of nonadherence among patients with COPD, the association of nonadherence with health outcomes, barriers to adherence in this patient population, and potential interventions.</p><p><strong>Expert opinion: </strong>Integrating research into practice involves assessing patients' adherence, identifying modifiable barriers to adherence, open discussion of these barriers with patients, and tailored interventions to address them. These interventions may include treatment of previously unrecognized comorbid disease, providing educational or behavioral interventions, optimizing prescribing strategies, use of adherence aids, or addressing cost and other access barriers. Electronic inhaler monitors are promising interventions for both monitoring and improving adherence. However, remaining concerns about integration into patient care, data management, cost, acceptability, and ethical and privacy issues must be overcome prior to their implementation in clinical practice.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10108356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pneumothorax, pneumomediastinum, and subcutaneous emphysema in hospitalized COVID-19 patients: incidence, clinical characteristics, and outcomes. 新冠肺炎住院患者的胸腔、纵隔气肿和皮下气肿:发病率、临床特征和结果。
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-09-11 DOI: 10.1080/17476348.2023.2254689
Aleksandra Murawska Baptista, Jorge Sinclair De Frías, Trisha Singh, Ananya Vasudhar, Jacob Guzzino, Waheed Khalili, Aysun Tekin, Vikas Bansal, Rahul Kashyap, William J Joyce, Patricia A Lewis, Devang Sanghavi, Tatjana Gavrancic, Pablo Moreno Franco

Background: Limited data is available on the incidence and outcomes of pneumothorax (PTX), pneumomediastinum (PNM), and subcutaneous emphysema (SCE) in COVID-19 patients. This study aimed to investigate the characteristics of these complications in hospitalized COVID-19 patients.

Research design and methods: A retrospective study was conducted, involving adult COVID-19 patients admitted to Mayo Clinic Florida from 03/2020-06/2022. Patients were divided into two groups based on the presence or absence of PTX/PNM/SCE.

Results: 1926 hospitalized patients with COVID-19 were included, of which 518 were admitted to the ICU. The incidence of PTX/PNM/SCE was 6.3%. Patients with these complications were more likely to be male, Asian, and unvaccinated. Conversely, they were less likely to have chronic obstructive pulmonary disease. Patients who developed PTX/PNM/SCE after 72 hours of admission were more likely to receive high-dose corticosteroids and for an extended duration. The affected group had an adjusted odds ratio for in-hospital mortality of 13.32 (95%CI, 8.19-21.59) and ICU admission of 9.14 (95%CI, 5.3-12.78) compared to the unaffected group.

Conclusion: Although the occurrence of PTX/PNM/SCE in hospitalized COVID-19 patients was rare, it was associated with worse outcomes. Corticosteroids may contribute to the pathogenesis of these complications; however, further studies are needed to investigate this relationship in more detail.

背景:关于新冠肺炎患者中的肺气肿(PTX)、纵隔气肿(PNM)和皮下气肿(SCE)的发病率和结果的数据有限。本研究旨在调查新冠肺炎住院患者的这些并发症的特征。研究设计和方法:进行了一项回顾性研究,涉及2020-06/2022年3月入住佛罗里达州梅奥诊所的成年新冠肺炎患者。根据PTX/PNM/SCE的存在与否,将患者分为两组。结果:纳入1926名新冠肺炎住院患者,其中518人入住ICU。PTX/PNM/SCE的发生率为6.3%。有这些并发症的患者更有可能是男性、亚洲人和未接种疫苗的人。相反,他们患慢性阻塞性肺病的可能性较小。72岁后出现PTX/PNM/SCE的患者 入院数小时更有可能接受高剂量皮质类固醇治疗并延长治疗时间。与未受影响组相比,受影响组的住院死亡率调整比值比为13.32(95%可信区间,8.19-21.59),ICU入院率为9.14(95%置信区间,5.3-12.78)。结论:尽管新冠肺炎住院患者PTX/PNM/SCE的发生率较低,但其与更严重的预后有关。皮质类固醇可能参与这些并发症的发病机制;然而,还需要进一步的研究来更详细地研究这种关系。
{"title":"Pneumothorax, pneumomediastinum, and subcutaneous emphysema in hospitalized COVID-19 patients: incidence, clinical characteristics, and outcomes.","authors":"Aleksandra Murawska Baptista,&nbsp;Jorge Sinclair De Frías,&nbsp;Trisha Singh,&nbsp;Ananya Vasudhar,&nbsp;Jacob Guzzino,&nbsp;Waheed Khalili,&nbsp;Aysun Tekin,&nbsp;Vikas Bansal,&nbsp;Rahul Kashyap,&nbsp;William J Joyce,&nbsp;Patricia A Lewis,&nbsp;Devang Sanghavi,&nbsp;Tatjana Gavrancic,&nbsp;Pablo Moreno Franco","doi":"10.1080/17476348.2023.2254689","DOIUrl":"10.1080/17476348.2023.2254689","url":null,"abstract":"<p><strong>Background: </strong>Limited data is available on the incidence and outcomes of pneumothorax (PTX), pneumomediastinum (PNM), and subcutaneous emphysema (SCE) in COVID-19 patients. This study aimed to investigate the characteristics of these complications in hospitalized COVID-19 patients.</p><p><strong>Research design and methods: </strong>A retrospective study was conducted, involving adult COVID-19 patients admitted to Mayo Clinic Florida from 03/2020-06/2022. Patients were divided into two groups based on the presence or absence of PTX/PNM/SCE.</p><p><strong>Results: </strong>1926 hospitalized patients with COVID-19 were included, of which 518 were admitted to the ICU. The incidence of PTX/PNM/SCE was 6.3%. Patients with these complications were more likely to be male, Asian, and unvaccinated. Conversely, they were less likely to have chronic obstructive pulmonary disease. Patients who developed PTX/PNM/SCE after 72 hours of admission were more likely to receive high-dose corticosteroids and for an extended duration. The affected group had an adjusted odds ratio for in-hospital mortality of 13.32 (95%CI, 8.19-21.59) and ICU admission of 9.14 (95%CI, 5.3-12.78) compared to the unaffected group.</p><p><strong>Conclusion: </strong>Although the occurrence of PTX/PNM/SCE in hospitalized COVID-19 patients was rare, it was associated with worse outcomes. Corticosteroids may contribute to the pathogenesis of these complications; however, further studies are needed to investigate this relationship in more detail.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe pediatric asthma endotypes: current limits and future perspectives. 严重儿童哮喘内型:当前限制和未来展望。
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-09-05 DOI: 10.1080/17476348.2023.2254234
Beatrice Andrenacci, Maria De Filippo, Martina Votto, Maria Sole Prevedoni Gorone, Mara De Amici, Stefania La Grutta, Gian Luigi Marseglia, Amelia Licari

Introduction: Although rare, pediatric severe therapy-resistant asthma (STRA) is a highly heterogeneous, resource-demanding disease that differs significantly from severe adult asthma and whose pathogenesis is still poorly understood.

Areas covered: This review summarizes the latest 10 years of English-written studies defining pediatric STRA endotypes using lung-specific techniques such as bronchoalveolar lavage and endobronchial biopsy. Results of the studies and limits on the field are discussed, together with some future perspectives.

Expert opinion: Over the years, it has become increasingly clear that 'one size does not fit all" in asthma. However, "Does an extremely tailored size fit more than one?'. Only using multicentric, longitudinal pediatric studies, will we be able to answer. Three issues could be particularly critical for future research. First, to provide, if existing, a distinction between prepuberal STRA and puberal STRA endotypes to understand the transition from pediatric to adult STRA and to design effective, tailored therapies in adolescents, usually suffering from poorer asthma control. Second, design early treatments for pediatric airway remodeling to preserve lifelong good lung function. Finally, to better characterize inflammation before and during biological therapies, to provide clues on whether to stop or change treatments.

引言:尽管罕见,但儿童重症治疗抵抗性哮喘(STRA)是一种高度异质性、资源需求高的疾病,与成人重症哮喘有很大不同,其发病机制仍知之甚少。所涵盖的领域:这篇综述总结了最近10年来使用支气管肺泡灌洗和支气管内膜活检等肺部特异性技术定义儿科STRA内型的英文书面研究。讨论了该领域的研究结果和局限性,以及一些未来的展望。专家意见:多年来,越来越清楚的是,哮喘患者“一个尺码不适合所有人”。然而,“一个非常定制的尺码适合不止一个吗?”。只有使用多中心、纵向的儿科研究,我们才能回答。有三个问题对未来的研究可能特别关键。首先,如果存在,提供青春期前STRA和青春期STRA内型之间的区别,以了解从儿童到成人STRA的过渡,并为通常哮喘控制较差的青少年设计有效的、量身定制的治疗方法。其次,设计儿童气道重塑的早期治疗方法,以保持终身良好的肺功能。最后,在生物治疗之前和期间更好地描述炎症,为是否停止或改变治疗提供线索。
{"title":"Severe pediatric asthma endotypes: current limits and future perspectives.","authors":"Beatrice Andrenacci,&nbsp;Maria De Filippo,&nbsp;Martina Votto,&nbsp;Maria Sole Prevedoni Gorone,&nbsp;Mara De Amici,&nbsp;Stefania La Grutta,&nbsp;Gian Luigi Marseglia,&nbsp;Amelia Licari","doi":"10.1080/17476348.2023.2254234","DOIUrl":"10.1080/17476348.2023.2254234","url":null,"abstract":"<p><strong>Introduction: </strong>Although rare, pediatric severe therapy-resistant asthma (STRA) is a highly heterogeneous, resource-demanding disease that differs significantly from severe adult asthma and whose pathogenesis is still poorly understood.</p><p><strong>Areas covered: </strong>This review summarizes the latest 10 years of English-written studies defining pediatric STRA endotypes using lung-specific techniques such as bronchoalveolar lavage and endobronchial biopsy. Results of the studies and limits on the field are discussed, together with some future perspectives.</p><p><strong>Expert opinion: </strong>Over the years, it has become increasingly clear that 'one size does not fit all\" in asthma. However, \"Does an extremely tailored size fit more than one?'. Only using multicentric, longitudinal pediatric studies, will we be able to answer. Three issues could be particularly critical for future research. First, to provide, if existing, a distinction between prepuberal STRA and puberal STRA endotypes to understand the transition from pediatric to adult STRA and to design effective, tailored therapies in adolescents, usually suffering from poorer asthma control. Second, design early treatments for pediatric airway remodeling to preserve lifelong good lung function. Finally, to better characterize inflammation before and during biological therapies, to provide clues on whether to stop or change treatments.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10651900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oscillometry in severe asthma: the state of the art and future perspectives. 严重哮喘的示波测量:技术现状和未来展望。
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-07-20 DOI: 10.1080/17476348.2023.2237872
Francesco Menzella, Leonardo Antonicelli, Marcello Cottini, Gianluca Imeri, Lorenzo Corsi, Fabiano Di Marco

Introduction: Approximately 3-10% of people with asthma have severe asthma (SA). Patients with SA have greater impairment in daily life and much higher costs. Even if asthma affects the entire bronchial tree, small airways have been recognized as the major site of airflow limitation. There are several tools for studying small airway dysfunction (SAD), but certainly the most interesting is oscillometry. Despite several studies, the clinical usefulness of oscillometry in asthma is still in question. This paper aims to provide evidence supporting the use of oscillometry to improve the management of SA in clinical practice.

Areas covered: In the ATLANTIS study, SAD was strongly evident across all severity. Various tools are available for evaluation of SAD, and certainly an integrated use of these can provide complete and detailed information. However, the most suitable method is oscillometry, implemented for clinical routine by using either small pressure impulses or small pressure sinusoidal waves.

Expert opinion: Oscillometry, despite its different technological implementations is the best tool for determining the impact of SAD on asthma and its control. Oscillometry will also be increasingly useful for choosing the appropriate drug, and there is ample room for a more widespread diffusion in clinical practice.

引言:大约3-10%的哮喘患者患有严重哮喘(SA)。SA患者在日常生活中的损伤更大,费用也高得多。即使哮喘影响整个支气管树,小气道也被认为是气流受限的主要部位。有几种研究小气道功能障碍(SAD)的工具,但最有趣的肯定是示波法。尽管进行了几项研究,但示波法在哮喘中的临床实用性仍然存在疑问。本文旨在为在临床实践中使用示波法改善SA的管理提供证据。涵盖的领域:在ATLANTIS的研究中,SAD在所有严重程度上都非常明显。有各种工具可用于评估SAD,当然,综合使用这些工具可以提供完整和详细的信息。然而,最合适的方法是示波法,通过使用小压力脉冲或小压力正弦波来实现临床常规。专家意见:尽管示波器的技术实现方式不同,但它是确定SAD对哮喘及其控制影响的最佳工具。示波法在选择合适的药物方面也将越来越有用,在临床实践中有更广泛的推广空间。
{"title":"Oscillometry in severe asthma: the state of the art and future perspectives.","authors":"Francesco Menzella,&nbsp;Leonardo Antonicelli,&nbsp;Marcello Cottini,&nbsp;Gianluca Imeri,&nbsp;Lorenzo Corsi,&nbsp;Fabiano Di Marco","doi":"10.1080/17476348.2023.2237872","DOIUrl":"10.1080/17476348.2023.2237872","url":null,"abstract":"<p><strong>Introduction: </strong>Approximately 3-10% of people with asthma have severe asthma (SA). Patients with SA have greater impairment in daily life and much higher costs. Even if asthma affects the entire bronchial tree, small airways have been recognized as the major site of airflow limitation. There are several tools for studying small airway dysfunction (SAD), but certainly the most interesting is oscillometry. Despite several studies, the clinical usefulness of oscillometry in asthma is still in question. This paper aims to provide evidence supporting the use of oscillometry to improve the management of SA in clinical practice.</p><p><strong>Areas covered: </strong>In the ATLANTIS study, SAD was strongly evident across all severity. Various tools are available for evaluation of SAD, and certainly an integrated use of these can provide complete and detailed information. However, the most suitable method is oscillometry, implemented for clinical routine by using either small pressure impulses or small pressure sinusoidal waves.</p><p><strong>Expert opinion: </strong>Oscillometry, despite its different technological implementations is the best tool for determining the impact of SAD on asthma and its control. Oscillometry will also be increasingly useful for choosing the appropriate drug, and there is ample room for a more widespread diffusion in clinical practice.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10119423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The argument for utilising magnetic resonance imaging as a tool for monitoring lung structure and function in pediatric patients. 利用磁共振成像作为监测儿科患者肺部结构和功能的工具的论点。
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-07-28 DOI: 10.1080/17476348.2023.2241355
Brandon Zanette, Mary-Louise C Greer, Theo J Moraes, Felix Ratjen, Giles Santyr

Introduction: Although historically challenging to perform in the lung, technological advancements have made Magnetic Resonance Imaging (MRI) increasingly applicable for pediatric pulmonary imaging. Furthermore, a wide array of functional imaging techniques has become available that may be leveraged alongside structural imaging for increasingly sensitive biomarkers, or as outcome measures in the evaluation of novel therapies.

Areas covered: In this review, recent technical advancements and modern methodologies for structural and functional lung MRI are described. These include ultrashort echo time (UTE) MRI, free-breathing contrast agent-free, functional lung MRI, and hyperpolarized gas MRI, amongst other techniques. Specific examples of the application of these methods in children are provided, principally drawn from recent research in asthma, bronchopulmonary dysplasia, and cystic fibrosis.

Expert opinion: Pediatric lung MRI is rapidly growing, and is well poised for clinical utilization, as well as continued research into early disease detection, disease processes, and novel treatments. Structure/function complementarity makes MRI especially attractive as a tool for increased adoption in the evaluation of pediatric lung disease. Looking toward the future, novel technologies, such as low-field MRI and artificial intelligence, mitigate some of the traditional drawbacks of lung MRI and will aid in improving access to MRI in general, potentially spurring increased adoption and demand for pulmonary MRI in children.

引言:尽管在历史上对肺部成像具有挑战性,但技术进步使磁共振成像(MRI)越来越适用于儿科肺部成像。此外,一系列广泛的功能成像技术已经可用,这些技术可以与结构成像一起用于越来越敏感的生物标志物,或者作为评估新疗法的结果指标。涵盖的领域:在这篇综述中,描述了结构和功能性肺MRI的最新技术进步和现代方法。其中包括超短回波时间(UTE)MRI、无自由呼吸造影剂、功能性肺MRI和超极化气体MRI等技术。提供了这些方法在儿童中应用的具体例子,主要来源于最近对哮喘、支气管肺发育不良和囊性纤维化的研究。专家意见:儿童肺部MRI正在迅速发展,并已做好临床应用的准备,以及对早期疾病检测、疾病过程和新治疗方法的持续研究。结构/功能的互补性使得MRI作为一种工具在评估儿童肺部疾病中越来越受欢迎。展望未来,低场MRI和人工智能等新技术将缓解肺部MRI的一些传统缺点,并将有助于改善MRI的普及率,这可能会刺激儿童对肺部MRI的采用和需求增加。
{"title":"The argument for utilising magnetic resonance imaging as a tool for monitoring lung structure and function in pediatric patients.","authors":"Brandon Zanette,&nbsp;Mary-Louise C Greer,&nbsp;Theo J Moraes,&nbsp;Felix Ratjen,&nbsp;Giles Santyr","doi":"10.1080/17476348.2023.2241355","DOIUrl":"10.1080/17476348.2023.2241355","url":null,"abstract":"<p><strong>Introduction: </strong>Although historically challenging to perform in the lung, technological advancements have made Magnetic Resonance Imaging (MRI) increasingly applicable for pediatric pulmonary imaging. Furthermore, a wide array of functional imaging techniques has become available that may be leveraged alongside structural imaging for increasingly sensitive biomarkers, or as outcome measures in the evaluation of novel therapies.</p><p><strong>Areas covered: </strong>In this review, recent technical advancements and modern methodologies for structural and functional lung MRI are described. These include ultrashort echo time (UTE) MRI, free-breathing contrast agent-free, functional lung MRI, and hyperpolarized gas MRI, amongst other techniques. Specific examples of the application of these methods in children are provided, principally drawn from recent research in asthma, bronchopulmonary dysplasia, and cystic fibrosis.</p><p><strong>Expert opinion: </strong>Pediatric lung MRI is rapidly growing, and is well poised for clinical utilization, as well as continued research into early disease detection, disease processes, and novel treatments. Structure/function complementarity makes MRI especially attractive as a tool for increased adoption in the evaluation of pediatric lung disease. Looking toward the future, novel technologies, such as low-field MRI and artificial intelligence, mitigate some of the traditional drawbacks of lung MRI and will aid in improving access to MRI in general, potentially spurring increased adoption and demand for pulmonary MRI in children.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10172554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Procalcitonin as a biomarker to guide treatments for patients with lower respiratory tract infections. 降钙素原作为指导下呼吸道感染患者治疗的生物标志物。
IF 3.9 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-08-28 DOI: 10.1080/17476348.2023.2251394
Ouriel Saura, Charles-Edouard Luyt

Introduction: Lower respiratory tract infections are amongst the main causes for hospital/intensive care unit admissions and antimicrobial prescriptions. In order to reduce antimicrobial pressure, antibiotic administration could be optimized through procalcitonin-based algorithms.

Areas covered: In this review, we discuss the performances of procalcitonin for the diagnosis and the management of community-acquired and ventilator-associated pneumonia. We provide up-to-date evidence and deliver clear messages regarding the purpose of procalcitonin to reduce unnecessary antimicrobial exposure.

Expert opinion: Antimicrobial pressure and resulting antimicrobial resistances are a major public health issue as well as a daily struggle in the management of patients with severe infectious diseases, especially in intensive care units where antibiotic exposure is high. Procalcitonin-guided antibiotic administration has proven its efficacy in reducing unnecessary antibiotic use in lower respiratory tract infections without excess in mortality, hospital length of stay or disease relapse. Procalcitonin-guided algorithms should be implemented in wards taking care of patients with severe infections. However, procalcitonin performances are different regarding the setting of the infection (community versus hospital-acquired infections) the antibiotic management (start or termination of antibiotic) as well as patient's condition (immunosuppressed or in shock) and we encourage the physicians to be aware of these limitations.

引言:下呼吸道感染是住院/重症监护室和开具抗菌药物处方的主要原因之一。为了降低抗菌压力,可以通过基于降钙素原的算法优化抗生素给药。涵盖领域:在这篇综述中,我们讨论了降钙素原在社区获得性和呼吸机相关肺炎的诊断和治疗中的表现。我们提供了最新的证据,并就降钙素原减少不必要的抗菌药物暴露的目的发出了明确的信息。专家意见:抗微生物压力和由此产生的抗微生物耐药性是一个主要的公共卫生问题,也是严重传染病患者管理中的日常斗争,尤其是在抗生素暴露量高的重症监护室。降钙素原指导的抗生素给药已证明其在减少下呼吸道感染中不必要的抗生素使用方面的有效性,而不会导致死亡率、住院时间或疾病复发。降钙素原引导的算法应该在照顾严重感染患者的病房中实施。然而,降钙素原的表现在感染环境(社区与医院获得性感染)、抗生素管理(抗生素的开始或终止)以及患者的病情(免疫抑制或休克)方面有所不同,我们鼓励医生意识到这些局限性。
{"title":"Procalcitonin as a biomarker to guide treatments for patients with lower respiratory tract infections.","authors":"Ouriel Saura,&nbsp;Charles-Edouard Luyt","doi":"10.1080/17476348.2023.2251394","DOIUrl":"10.1080/17476348.2023.2251394","url":null,"abstract":"<p><strong>Introduction: </strong>Lower respiratory tract infections are amongst the main causes for hospital/intensive care unit admissions and antimicrobial prescriptions. In order to reduce antimicrobial pressure, antibiotic administration could be optimized through procalcitonin-based algorithms.</p><p><strong>Areas covered: </strong>In this review, we discuss the performances of procalcitonin for the diagnosis and the management of community-acquired and ventilator-associated pneumonia. We provide up-to-date evidence and deliver clear messages regarding the purpose of procalcitonin to reduce unnecessary antimicrobial exposure.</p><p><strong>Expert opinion: </strong>Antimicrobial pressure and resulting antimicrobial resistances are a major public health issue as well as a daily struggle in the management of patients with severe infectious diseases, especially in intensive care units where antibiotic exposure is high. Procalcitonin-guided antibiotic administration has proven its efficacy in reducing unnecessary antibiotic use in lower respiratory tract infections without excess in mortality, hospital length of stay or disease relapse. Procalcitonin-guided algorithms should be implemented in wards taking care of patients with severe infections. However, procalcitonin performances are different regarding the setting of the infection (community versus hospital-acquired infections) the antibiotic management (start or termination of antibiotic) as well as patient's condition (immunosuppressed or in shock) and we encourage the physicians to be aware of these limitations.</p>","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10304051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Respiratory Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1